Dapaglip 10 mg (Tablet)
Unit Price: ৳ 30.00 (2 x 10: ৳ 600.00)
Strip Price: ৳ 300.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dapagliflozin propanediol |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pharmacology
- Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
- Reduces reabsorption of filtered glucose
- Lowers the renal threshold for glucose
- Increases urinary glucose excretion
Dosage & Administration
- Recommended starting dose of 5 mg once daily for adults
- Can be increased to 10 mg once daily for additional glycemic control
- Assessment of renal function recommended prior to initiation
- Not recommended in patients with eGFR less than 60 mL/min/1.73 m^2
- No established safety and efficacy in children and adolescents
Interaction
- May add to the diuretic effect of thiazide and loop diuretics
- May interact with insulin, insulin secretagogues, antihypertensives, pioglitazone, agents affecting renal function, GLP-1 agonists, valsartan, rifampin, mefenamic acid
Contraindications
- Known hypersensitivity to Dapagliflozin or excipients
- Severe renal impairment
- End-stage renal diseases or patients on dialysis
Side Effects
- Hypotension
- Ketoacidosis
- Acute kidney injury
- Impairment in renal function
- Urosepsis and pyelonephritis
- Hypoglycemia with concomitant use with insulin
- Genital mycotic infections
- Increases in low-density lipoprotein cholesterol (LDL-C)
- Nasopharyngitis
- Urinary tract infection
- Bladder cancer
Pregnancy & Lactation
- Pregnancy category C
- No adequate data in pregnant women
- Should be used during pregnancy only if potential benefit justifies potential risk to the fetus
- Not known if excreted in human milk
- Should not be used during lactation
Precautions & Warnings
- Assess volume status and correct hypovolemia before initiation
- Monitor renal function during therapy
- Consider lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia
- Not to be used in patients with active bladder cancer
- No established macrovascular risk reduction evidence
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Store in a cool place below 30°C
- Dry place protected from light
- Keep away from the reach of children